Preliminary results from a Phase 1/2 study presented at ESMO GI 2026 evaluate the safety and efficacy of zoldonrasib (RMC-9805) combined with chemotherapy for first-line treatment of RAS G12D-mutated metastatic pancreatic adenocarcinoma. Zoldonrasib is an oral, selective inhibitor designed to target the RAS G12D mutation, which occurs in approximately 40% of pancreatic cancer cases and currently lacks approved targeted therapies. The study assesses the drug in combination with standard regimens like mFOLFIRINOX or gemcitabine/nab-paclitaxel.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.